In 2019, pharmaceutical companies completed 39 asset sales, some of which were multiple sales

[pharmaceutical network industry trends] according to the statistics of pharmaceutical industry analysts, in 2019, pharmaceutical companies completed 39 asset sales, compared with 111 asset sales in 2017-2019 Some of these pharmaceutical companies sell assets in order to obtain cash flow, help business expansion and reduce debt; some are to optimize financial statements Recently, many pharmaceutical companies, such as Haizheng pharmaceutical, humanwell pharmaceutical, and tisley, have issued asset sales announcements successively, some of which are for multiple sales Haizheng pharmaceutical has sold assets for many times Since 2019, Haizheng pharmaceutical has issued the announcement of selling assets for many times As early as March 2019, Haizheng pharmaceutical announced that it would sell idle properties in Beijing, Shanghai, Hangzhou and Jiaojiang through property rights trading institutions In May 2019, Haizheng pharmaceutical announced that it plans to transfer 20.24% of the equity of Zhejiang Daoming Pharmaceutical Technology Co., Ltd with the appraisal value of 138 million yuan In September 2019, Haizheng pharmaceutical sold 23 peacocks raised in the park to employees at a low price On November 5, 2019, Haizheng Pharmaceutical Co., Ltd submitted the listing application to Shanghai stock exchange for the real estate of No 16 and No 17 factory buildings, Lane 4855, Guangfulin Road, Xiaokunshan Town, Songjiang District, Shanghai, and room 1901 and room 1902, building 3, No 23, nanbinhe Road, Xuanwu District, Beijing On January 7, 2020, Haizheng pharmaceutical announced that on January 6, the auction of 5 apartments of the company located in block a, Junyue building, Jiaojiang District, Taizhou city was successful, with a total turnover of 1.82 million yuan According to incomplete statistics, since the beginning of 2019, Haizheng pharmaceutical has recovered 3.771 billion yuan by selling assets It is equivalent to three times of the net profit attributable to the parent company of RMB 1255 million in the first three quarters of 2019 of Haizheng pharmaceutical However, in the first three quarters of 2019, Haizheng pharmaceutical's current liabilities totaled 11.213 billion yuan, higher than its current assets of 9.251 billion yuan In addition, due to the failure of research and development of new drugs, Haizheng pharmaceutical also announced that it plans to withdraw 1.317 billion yuan of assets, which will reduce the total net profit of 1.728 billion yuan in 2019 It can be seen that although asset sales can increase performance, it is still only a drop in the bucket for its year-end statement data Humanwell sold real estate on the evening of December 30, 2019, humanwell announced that Zhongxiang medical, a wholly-owned subsidiary of the company, intends to sell all the real estate in the new hospital area of Zhongxiang people's hospital to Xingrui assets The accumulated construction investment of the project is about 1 billion yuan, and the total sale price will be determined according to the final account audit results of the project According to preliminary calculation, the investment income of the project is about 40 million yuan In 2018, Zhongxiang medical realized an operating revenue of 36.0945 million yuan and a net profit of 14.8115 million yuan Humanwell said that the company actively promoted business focus and asset optimization, and decided to gradually withdraw from the segments with no obvious competitive advantage or weak synergy, such as medical services Sales of Tianshi by Tianshi was impacted by the "two vote system", and many pharmaceutical companies divested their pharmaceutical business sector On December 16, 2019, Tianshili announced that the company plans to sell all its shares in Tianshi marketing company, and has signed the framework agreement with Chongqing pharmaceutical (Group) Co., Ltd on relevant matters Tianshi marketing is mainly responsible for tianshiyuan pharmaceutical business segment, with total operating revenue of RMB 11.7 billion and net profit of RMB 100 million in 2018, accounting for 64.81% and 6.30% of total operating revenue and net profit of Tianshili in 2018, respectively It is reported that through the sale of assets, Tianshili will further focus on the pharmaceutical industry, continue to promote the coordinated development of modern Chinese medicine, biological medicine and chemical medicine, and build innovative pharmaceutical R & D clusters.